<DOC>
	<DOCNO>NCT02689518</DOCNO>
	<brief_summary>Clinical genetic evaluation individual treat intravitreal aflibercept injection ( Eylea ) neovascular age-related macular degeneration ( wet AMD )</brief_summary>
	<brief_title>EAGLE : Evaluating Genotypes Using Intravitreal Aflibercept Injection</brief_title>
	<detailed_description>Clinical genetic assessment treatment response patient age-related macular degeneration use intravitreal aflibercept injection . This study seek determine different genetic polymorphism vascular endothelial growth factor A ( VEGF-A ) HtrA serine peptidase 1 ( HTRA1 ) gene correlate response intravitreal aflibercept injection therapy .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>1 . Age ≥ 50 year 2 . Naïve neovascular wetAMD ( receive treatment ) 3 . Willing able comply clinic visit studyrelated procedure 4 . Provide sign informed consent 1 . Previous therapy study eye AMD retinal disease may use treatment AMD 2 . Previous subfoveal focal laser photocoagulation involve foveal center study eye 3 . History vitrectomy , submacular surgery , surgical intervention AMD study eye 4 . Any concurrent intraocular condition study eye ( e.g . diabetic retinopathy glaucoma ) , opinion investigator , could either 4.1 require medical surgical intervention study period prevent treat visual loss might result condition , 4.2 allow progress untreated , could likely contribute loss least 2 Snellen equivalent line best correct visual acuity study period 5 . Active intraocular inflammation ( grade trace ) study eye , history idiopathic autoimmuneassociated uveitis either eye 6 . Current vitreous hemorrhage study eye 7 . History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye 8 . Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye 9 . Aphakia , ACIOL , unstable PCIOL 10 . Uncontrolled glaucoma study eye ( defined intraocular pressure ≥30 mmHg despite treatment antiglaucoma medication ) 11 . Pregnant breastfeed woman 12 . Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) 13 . Any condition investigator believe would pose significant hazard patient investigational therapy initiate *Contraception require men document vasectomy . **Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AMD</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>Macular degeneration</keyword>
	<keyword>Wet macular degeneration</keyword>
	<keyword>Neovascularization</keyword>
	<keyword>Retina</keyword>
	<keyword>Retinal degeneration</keyword>
</DOC>